Kymera Therapeutics, Inc. SEC Filings

Form 144 filed for Kymera Therapeutics, Inc. (KYMR) reporting a proposed sale of 79,220 shares of common stock through Morgan Stanley Smith Barney LLC on 09/17/2025. The filing shows the shares were acquired the same day by exercise of stock options from the issuer and were paid in cash. The aggregate market value of the shares at the proposed sale is reported as $3,864,351.60 and the company has 71,497,597 shares outstanding per the form. No other securities sales in the past three months are reported and the filer certifies they do not possess undisclosed material adverse information.

Kymera Therapeutics insider transactions by CEO and director Nello Mainolfi on 09/16/2025: The filing shows the exercise of a fully vested stock option with a $2.08 exercise price that converted into 30,000 shares, and an offsetting sale of 30,000 shares at $49. Following these transactions the reporting person beneficially owned 660,482 shares.

The filing notes these trades were executed under a Rule 10b5-1 trading plan adopted September 6, 2024, and the derivative shares underlying the option are fully vested and exercisable with an expiration date of November 13, 2029.

Kymera Therapeutics (KYMR) Form 144 notice reports a proposed sale of 30,000 common shares. The shares are scheduled to be sold through UBS Financial Services on NASDAQ on 09/16/2025 with an aggregate market value of $1,470,000. The filing states 71,497,597 shares outstanding. The 30,000 shares were acquired on 09/16/2025 by exercise of stock options from the issuer and payment was in cash on the same date. The filer reports no securities sold in the past three months and affirms no undisclosed material adverse information.

Kymera Therapeutics insider grant to Chief Legal Officer The filing shows that Brian Adams, Chief Legal Officer of Kymera Therapeutics (KYMR), was granted 52,500 restricted stock units (RSUs) and a stock option covering 105,000 shares on September 3, 2025. The RSUs vest in four equal annual installments beginning September 3, 2026, subject to continued employment. The option has an exercise price of $43.30, vests 25% on September 3, 2026, with the remainder in 36 equal monthly installments, and expires on September 2, 2035. Following the grants, Mr. Adams directly beneficially owns 52,500 shares from the RSUs and 105,000 option shares reported.

Kymera Therapeutics, Inc. (KYMR) is reported as having significant institutional ownership by Wellington Management and affiliated entities. The filing shows an aggregate beneficial ownership of 5,372,061 shares, representing approximately 7.66% of the outstanding common stock. The reporting parties state they have no sole voting or dispositive power and instead hold shared voting power of 4,872,818 shares and shared dispositive power of 5,372,061 shares. The securities are owned of record by clients of Wellington investment advisers and the filing is submitted on Schedule 13G, with a certification that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control.

Kymera Therapeutics (KYMR) reported Q2 2025 interim results showing strong liquidity while continuing to invest heavily in R&D. The company held $963.1 million of combined cash, cash equivalents and marketable securities at June 30, 2025 and completed a June follow-on that generated aggregate gross proceeds of approximately $288.4 million.

Collaboration revenue totaled $11.5 million for the quarter and $33.6 million for the six months, mainly from the Sanofi collaboration; Kymera also received a $40.0 million upfront payment under an option agreement with Gilead. R&D expense rose to $158.6 million for the six months, contributing to a six-month net loss of $142.2 million and an accumulated deficit of $896.8 million.

Kymera Therapeutics announced that it reported its financial results for the quarter ended June 30, 2025 and furnished the related press release as Exhibit 99.1 to a Current Report on Form 8-K. The filing states the press release is being furnished and not deemed "filed" under the Exchange Act, and the cover page includes interactive data.

The Form 8-K text does not include the underlying financial figures; readers are referred to the furnished press release for detailed results. The report is signed by Nello Mainolfi, Ph.D., President and Chief Executive Officer, confirming the submission of the exhibit.